Acquisitions

Acquisitions completed from the 2025 financial year are distributed among the Group’s business areas as follows:

			Net Sales,	Number of
Company	Country	Time	SEKm*	employees*	Business area
Edge Medical Ltd.	UK	April 2025	90	20	Medtech
Pharmacold A/S	Denmark	December 2025	38	20	Labtech
Opitek International ApS	Denmark	December 2025	12	2	Medtech
BioSpectrum Ltd.	UK	March 2026	75	16	Medtech
CoaChrom Diagnostica GmbH	Austria	April 2026	110	10	Labtech
Unicam Sistemas Analíticos Lda	Portugal	September 2026	110	20	Labtech
			435	88
*Refers to conditions at the time of acquisition on a full-year basis.

In March all shares in BioSpectrum Ltd., United Kingdom, were acquired. BioSpectrum is a rapidly growing distributor of surgical solutions within urology, gynaecology and general surgery in the UK market. The company has annual sales of approximately GBP 6 million and 16 employees.

In April all shares in the Austrian company CoaChrom Diagnostica GmbH were acquired. CoaChrom is a distributor focusing on advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry. The company has annual sales of approximately EUR 10 million and 10 employees.

In September, all shares in the Portuguese company Unicam Sistemas Analíticos Lda were acquired. Unicam distributes advanced analytical laboratory equipment to universities, research institutes and industrial customers. The company has annual revenue of approximately EUR 10 million and 20 employees.

Net assets of acquired companies at the acquisition date

Fair value	Sep 30
SEKm	2026
Intangible non-current assets	183
Other non-current assets	11
Inventories	42
Other current assets	134
Deferred tax liability/tax asset	-41
Other liabilities	-82
Acquired net assets	247
Goodwill	337
Consideration¹	584
Less:
Cash and cash equivalents in acquired businesses	-65
Contingent consideration not yet paid	-142
Effect on the Group’s cash and cash equivalents	377
¹The consideration is stated excluding acquisition expenses.

Acquired companies
The purchase price allocations are preliminary, as the net assets of the acquired companies have not yet been finally determined. For this year’s acquisitions, the purchase consideration exceeded the carrying amount of the net assets of the acquired companies, resulting in goodwill and intangible assets.

Goodwill
The goodwill arising from the acquisitions is attributable to the expectation that the Group’s position in the relevant markets will be strengthened, as well as the expertise developed in the acquired companies.

Contingent consideration
The contingent considerations included in the acquisitions are usually linked to the performance development of the respective companies.

During the interim period, contingent consideration of SEK 23 million relating to acquisitions completed in previous years was paid to the sellers of BonsaiLab, Pharmacold and Opitek.

Remeasurement of liabilities for contingent consideration relating to previous acquisitions resulted in a net income of SEK 32 million. These were reversed during the quarter and recognized in other operating income and expenses.

Transaction costs
Transaction costs for acquisitions amount to a total of SEK 5 million and are recognized in selling expenses.

Revenue and earnings from acquired businesses
The acquisitions completed during the year have, from their respective acquisition dates, contributed a total of SEK 114 million to the Group’s net sales and SEK 36 million to EBITA.

Had the acquired companies been consolidated from January 1, 2026, net sales and EBITA would have amounted to SEK 293 million and SEK 91 million, respectively.

Acquisitions after the end of the interim period
In October, 85 percent of the shares in the German company Lehnen GmbH were acquired. Lehnen manufactures products and system solutions for accessible and functionally adapted bathrooms. The company has annual sales of approximately EUR 5 million and around 30 employees.